EVAX

Evaxion A/S

Add to Watchlist

Advanced Chart

2.830

+0.15(5.597%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.840

Open

2.700

VWAP

2.68

Vol

82.79K

Mkt Cap

17.88M

Low

2.620

Amount

221.80K

EV/EBITDA(TTM)

Total Shares

5.41M

-914.59K

EV/OCF(TTM)

P/S(TTM)

17.94

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

0.00

-100%

0.00

-100%

60.00K

+17.65%

Estimates Revision

The market is revising No Change the revenue expectations for Evaxion A/S (EVAX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 91.22%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+91.22%

In Past 3 Month

2 Analyst Rating

253.36% Upside

Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is 10.00 USD with a low forecast of 6.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

253.36% Upside

Current: 2.830

Low

6.00

Averages

10.00

High

14.00

253.36% Upside

Current: 2.830

Low

6.00

Averages

10.00

High

14.00

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$14

2025-04-02

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$14

2025-04-02

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$14

2025-02-20

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$14

2025-02-20

Reiterates

Strong Buy

Reason

Lake Street

Thomas Flaten

Strong Buy

Maintains

$35 → $6

2025-02-04

Reason

Lake Street

Thomas Flaten

Price Target

$35 → $6

2025-02-04

Maintains

Strong Buy

Reason

Evaxion Biotech announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs. MSD Global Health Innovation Fund, who became an Evaxion shareholder in December 2023, is also participating in this offering along with healthcare-focused investment funds. There is also participation from Evaxion's Board of Directors and Management. The warrants will have an exercise price of $2.71 per ADS, will be exercisable immediately upon issuance and will expire five years following the date of issuance. Each ADS represents fifty ordinary shares of the company. The closing of the offering is expected to occur on or about January 31, 2025, subject to the satisfaction of customary closing conditions. Lake Street Capital Markets and Jones are acting as the exclusive placement agents for the offering. The gross proceeds to the company from the offering are expected to be $10.8M, before deducting the placement agent's fees and other offering expenses payable by the company. The company intends to use the net proceeds of this offering to advance the company's preclinical and clinical pipeline, and for continuing operating expenses and working capital.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$14

2025-02-03

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$14

2025-02-03

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$14

2024-11-01

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$14

2024-11-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$14

2024-09-26

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$14

2024-09-26

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Evaxion A/S (EVAX.O) is -1.20, compared to its 5-year average forward P/E of -4.15. For a more detailed relative valuation and DCF analysis to assess Evaxion A/S 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.15

Current PE

-1.20

Overvalued PE

0.94

Undervalued PE

-9.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.67

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.21

Undervalued EV/EBITDA

-3.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.49

Current PS

0.00

Overvalued PS

26.86

Undervalued PS

-5.88